Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660890 · ClinicalTrials.gov registry record · Phase 1
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT04660890: Completed Phase 1 study, sponsored by Alexion Pharmaceuticals.
NCT04660890 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04660890, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.
Primary Outcome
Twelve-lead electrocardiograms (ECGs) will be extracted from continuous (Holter) recordings.
Interventions
- DRUG Moxifloxacin
- DRUG ALXN2050
- DRUG ALXN2050-matching Placebo
- DRUG Moxifloxacin-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-12-12 |
| Est. Completion | 2021-03-16 |
| Phase | Phase 1 |
What the finished NCT04660890 record still lists
NCT04660890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT04660890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04660890 about?
NCT04660890 is a clinical study titled "A Study of the Cardiac Effects of ALXN2050 in Healthy Adults". This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.
What is the current status of trial NCT04660890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2020-12-12. Estimated completion is 2021-03-16.
What interventions are being tested in trial NCT04660890?
The interventions under investigation include: Moxifloxacin (DRUG), ALXN2050 (DRUG), ALXN2050-matching Placebo (DRUG), Moxifloxacin-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT04660890?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04660890's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI